查看購物車
  • Simplified Chinese
  • English
  • Japanese
寡核苷酸綴合物：全球市佔率和排名、總收入和需求預測（2025-2031年）
市場調查報告書
商品編碼
1876523

寡核苷酸綴合物：全球市佔率和排名、總收入和需求預測（2025-2031年）

Oligonucleotide Conjugates - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球寡核苷酸偶聯物市場規模估計為 1.692 億美元，預計到 2031 年將達到 17.688 億美元，在預測期（2025-2031 年）內以 40.36% 的複合年成長率成長。

2024 年北美寡核苷酸偶聯物市場價值為 7,298 萬美元，預計到 2031 年將達到 7.199 億美元，在預測期（2025-2031 年）內複合年成長率為 39.28%。

2024 年亞太地區寡核苷酸偶聯物市場價值為 4,389 萬美元，預計到 2031 年將達到 5.4267 億美元，在預測期（2025-2031 年）內複合年成長率為 43.72%。

2024 年歐洲寡核苷酸偶聯物市場價值為 4,529 萬美元，預計到 2031 年將達到 4.4326 億美元，在預測期（2025-2031 年）內複合年成長率為 38.89%。

截至2024年，全球寡核苷酸偶聯物領域的主要企業包括藥明泰德、百康、龍沙、百奧泉、金斯瑞、美迪德（中藥科技）、藥明康德、百奧合成、卡內卡株式會社（歐諾泰克）等。全球前五大公司將佔據約72%的市場佔有率（按銷售額計）。

本報告旨在按地區/國家、類型和應用對全球寡核苷酸綴合物市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

寡核苷酸偶聯物市場規模、估算和預測以銷售收入為指標，以2024年為基準年，並包含2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並就寡核苷酸偶聯物做出明智的商業決策。

市場區隔

公司

  • WuXi TIDES
  • Bachem
  • Lonza
  • BioSpring
  • GenScript
  • Medtide（CPC Scientific）
  • Kaneka Corporation（Eurogentec）
  • Olon（GTP Bioways）
  • Abzena
  • 3PBIOVIAN
  • Bio-Synthesis Inc
  • ChemExpress
  • Creative Biolabs
  • HitGen
  • Pharmaron
  • Suzhou Biosyntech
  • Creative Biogene（IntegrateRNA）

按類型分類的細分市場

  • 寡核苷酸-胜肽
  • 寡核苷酸抗體
  • 寡核苷酸-GalNAc
  • 寡核苷酸-脂質
  • 其他

應用領域

  • 基因治療
  • 藥物輸送
  • 疫苗研發

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 英國
    • 瑞士
    • 比利時
    • 法國
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲

The global market for Oligonucleotide Conjugates was estimated to be worth US$ 169.2 million in 2024 and is forecast to a readjusted size of US$ 1,768.8 million by 2031 with a CAGR of 40.36% during the forecast period 2025-2031.

North American market for Oligonucleotide Conjugates was valued at $ 72.98 million in 2024 and will reach $ 719.9 million by 2031, at a CAGR of 39.28% during the forecast period of 2025 through 2031.

Asia-Pacific market for Oligonucleotide Conjugates was valued at $ 43.89 million in 2024 and will reach $ 542.67 million by 2031, at a CAGR of 43.72% during the forecast period of 2025 through 2031.

Europe market for Oligonucleotide Conjugates was valued at $ 45.29 million in 2024 and will reach $ 443.26 million by 2031, at a CAGR of 38.89% during the forecast period of 2025 through 2031.

The global key companies of Oligonucleotide Conjugates include WuXi TIDES, Bachem, Lonza, BioSpring, GenScript, Medtide (CPC Scientific), Pharmaron, Bio-Synthesis Inc, and Kaneka Corporation (Eurogentec), etc. in 2024, the global five largest players hold a share approximately 72% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Conjugates, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Conjugates by region & country, by Type, and by Application.

The Oligonucleotide Conjugates market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Conjugates.

Market Segmentation

By Company

  • WuXi TIDES
  • Bachem
  • Lonza
  • BioSpring
  • GenScript
  • Medtide(CPC Scientific)
  • Kaneka Corporation(Eurogentec)
  • Olon(GTP Bioways)
  • Abzena
  • 3PBIOVIAN
  • Bio-Synthesis Inc
  • ChemExpress
  • Creative Biolabs
  • HitGen
  • Pharmaron
  • Suzhou Biosyntech
  • Creative Biogene (IntegrateRNA)

Segment by Type

  • Oligonucleotide-Peptide
  • Oligonucleotide-Antibody
  • Oligonucleotide-GalNAc
  • Oligonucleotide-Lipid
  • Other

Segment by Application

  • Gene Therapy
  • Drug Delivery
  • Vaccine Development

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • U.K.
    • Switzerland
    • Belgium
    • France
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Oligonucleotide Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Oligonucleotide Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Oligonucleotide Conjugates in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Oligonucleotide Conjugates Product Introduction
  • 1.2 Global Oligonucleotide Conjugates Market Size Forecast (2020-2031)
  • 1.3 Oligonucleotide Conjugates Market Trends & Drivers
    • 1.3.1 Oligonucleotide Conjugates Industry Trends
    • 1.3.2 Oligonucleotide Conjugates Market Drivers & Opportunity
    • 1.3.3 Oligonucleotide Conjugates Market Challenges
    • 1.3.4 Oligonucleotide Conjugates Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Oligonucleotide Conjugates Players Revenue Ranking (2024)
  • 2.2 Global Oligonucleotide Conjugates Revenue by Company (2020-2025)
  • 2.3 Key Companies Oligonucleotide Conjugates Product Offered
  • 2.4 Key Companies Time to Establish
  • 2.5 Oligonucleotide Conjugates Market Competitive Analysis
    • 2.5.1 Oligonucleotide Conjugates Market Concentration Rate (2020-2025)
    • 2.5.2 Global 5 and 10 Largest Companies by Oligonucleotide Conjugates Revenue in 2024
    • 2.5.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024)
  • 2.6 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Oligonucleotide-Peptide
    • 3.1.2 Oligonucleotide-Antibody
    • 3.1.3 Oligonucleotide-GalNAc
    • 3.1.4 Oligonucleotide-Lipid
    • 3.1.5 Other
  • 3.2 Global Oligonucleotide Conjugates Sales Value by Type
    • 3.2.1 Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Oligonucleotide Conjugates Sales Value, by Type (2020-2031)
    • 3.2.3 Global Oligonucleotide Conjugates Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Gene Therapy
    • 4.1.2 Drug Delivery
    • 4.1.3 Vaccine Development
  • 4.2 Global Oligonucleotide Conjugates Sales Value by Application
    • 4.2.1 Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Oligonucleotide Conjugates Sales Value, by Application (2020-2031)
    • 4.2.3 Global Oligonucleotide Conjugates Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Oligonucleotide Conjugates Sales Value by Region
    • 5.1.1 Global Oligonucleotide Conjugates Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Oligonucleotide Conjugates Sales Value by Region (2020-2025)
    • 5.1.3 Global Oligonucleotide Conjugates Sales Value by Region (2026-2031)
    • 5.1.4 Global Oligonucleotide Conjugates Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Oligonucleotide Conjugates Sales Value, 2020-2031
    • 5.2.2 North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031
    • 5.3.2 Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Oligonucleotide Conjugates Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Oligonucleotide Conjugates Sales Value, 2020-2031
    • 5.5.2 South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Oligonucleotide Conjugates Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.3.2 United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.4.2 Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.5.2 China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.6.2 Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.7.2 South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.8 Australia
    • 6.8.1 Australia Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.8.2 Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Australia Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Oligonucleotide Conjugates Sales Value, 2020-2031
    • 6.9.2 India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 WuXi TIDES
    • 7.1.1 WuXi TIDES Profile
    • 7.1.2 WuXi TIDES Main Business
    • 7.1.3 WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions
    • 7.1.4 WuXi TIDES Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
    • 7.1.5 WuXi TIDES Recent Developments
  • 7.2 Bachem
    • 7.2.1 Bachem Profile
    • 7.2.2 Bachem Main Business
    • 7.2.3 Bachem Oligonucleotide Conjugates Products, Services and Solutions
    • 7.2.4 Bachem Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Bachem Recent Developments
  • 7.3 Lonza
    • 7.3.1 Lonza Profile
    • 7.3.2 Lonza Main Business
    • 7.3.3 Lonza Oligonucleotide Conjugates Products, Services and Solutions
    • 7.3.4 Lonza Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Lonza Recent Developments
  • 7.4 BioSpring
    • 7.4.1 BioSpring Profile
    • 7.4.2 BioSpring Main Business
    • 7.4.3 BioSpring Oligonucleotide Conjugates Products, Services and Solutions
    • 7.4.4 BioSpring Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
    • 7.4.5 BioSpring Recent Developments
  • 7.5 GenScript
    • 7.5.1 GenScript Profile
    • 7.5.2 GenScript Main Business
    • 7.5.3 GenScript Oligonucleotide Conjugates Products, Services and Solutions
    • 7.5.4 GenScript Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.6 Medtide (CPC Scientific)
    • 7.6.1 Medtide (CPC Scientific) Profile
    • 7.6.2 Medtide (CPC Scientific) Main Business
    • 7.6.3 Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions
    • 7.6.4 Medtide (CPC Scientific) Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)
    • 7.6.5 Medtide (CPC Scientific) Recent Developments
  • 7.7 Kaneka Corporation (Eurogentec)
    • 7.7.1 Kaneka Corporation (Eurogentec) Profile
    • 7.7.2 Kaneka Corporation (Eurogentec) Main Business
    • 7.7.3 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions
    • 7.7.4 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.8 Olon (GTP Bioways)
    • 7.8.1 Olon (GTP Bioways) Profile
    • 7.8.2 Olon (GTP Bioways) Main Business
    • 7.8.3 Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions
    • 7.8.4 Olon (GTP Bioways) Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
    • 7.8.5 Olon (GTP Bioways) Recent Developments
  • 7.9 Abzena
    • 7.9.1 Abzena Profile
    • 7.9.2 Abzena Main Business
    • 7.9.3 Abzena Oligonucleotide Conjugates Products, Services and Solutions
    • 7.9.4 Abzena Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.10 3PBIOVIAN
    • 7.10.1 3PBIOVIAN Profile
    • 7.10.2 3PBIOVIAN Main Business
    • 7.10.3 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions
    • 7.10.4 3PBIOVIAN Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025)
  • 7.11 Bio-Synthesis Inc
    • 7.11.1 Bio-Synthesis Inc Profile
    • 7.11.2 Bio-Synthesis Inc Main Business
    • 7.11.3 Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions
    • 7.11.4 Bio-Synthesis Inc Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.12 ChemExpress
    • 7.12.1 ChemExpress Profile
    • 7.12.2 ChemExpress Main Business
    • 7.12.3 ChemExpress Oligonucleotide Conjugates Products, Services and Solutions
    • 7.12.4 ChemExpress Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
  • 7.13 Creative Biolabs
    • 7.13.1 Creative Biolabs Profile
    • 7.13.2 Creative Biolabs Main Business
    • 7.13.3 Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions
    • 7.13.4 Creative Biolabs Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)
  • 7.14 HitGen
    • 7.14.1 HitGen Profile
    • 7.14.2 HitGen Main Business
    • 7.14.3 HitGen Oligonucleotide Conjugates Products, Services and Solutions
    • 7.14.4 HitGen Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025)
  • 7.15 Pharmaron
    • 7.15.1 Pharmaron Profile
    • 7.15.2 Pharmaron Main Business
    • 7.15.3 Pharmaron Oligonucleotide Conjugates Products, Services and Solutions
    • 7.15.4 Pharmaron Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)
  • 7.16 Suzhou Biosyntech
    • 7.16.1 Suzhou Biosyntech Profile
    • 7.16.2 Suzhou Biosyntech Main Business
    • 7.16.3 Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions
    • 7.16.4 Suzhou Biosyntech Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025)
  • 7.17 Creative Biogene (IntegrateRNA)
    • 7.17.1 Creative Biogene (IntegrateRNA) Profile
    • 7.17.2 Creative Biogene (IntegrateRNA) Main Business
    • 7.17.3 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions
    • 7.17.4 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025)

8 Industry Chain Analysis

  • 8.1 Oligonucleotide Conjugates Industrial Chain
  • 8.2 Oligonucleotide Conjugates Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
    • 10.1.2 Data Source
  • 10.2 Author Details
  • 10.3 Disclaimer
  • Table 1. Oligonucleotide Conjugates Market Trends
  • Table 2. Oligonucleotide Conjugates Market Drivers & Opportunity
  • Table 3. Oligonucleotide Conjugates Market Challenges
  • Table 4. Oligonucleotide Conjugates Market Restraints
  • Table 5. Global Oligonucleotide Conjugates Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Oligonucleotide Conjugates Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Oligonucleotide Conjugates Product Type
  • Table 8. Key Companies Time to Establish
  • Table 9. Global Oligonucleotide Conjugates Companies Market Concentration Ratio (CR5 and HHI)
  • Table 10. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024)
  • Table 11. Mergers & Acquisitions, Expansion Plans
  • Table 12. Global Oligonucleotide Conjugates Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 13. Global Oligonucleotide Conjugates Sales Value by Type (2020-2025) & (US$ Million)
  • Table 14. Global Oligonucleotide Conjugates Sales Value by Type (2026-2031) & (US$ Million)
  • Table 15. Global Oligonucleotide Conjugates Sales Market Share in Value by Type (2020-2025)
  • Table 16. Global Oligonucleotide Conjugates Sales Market Share in Value by Type (2026-2031)
  • Table 17. Global Oligonucleotide Conjugates Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 18. Global Oligonucleotide Conjugates Sales Value by Application (2020-2025) & (US$ Million)
  • Table 19. Global Oligonucleotide Conjugates Sales Value by Application (2026-2031) & (US$ Million)
  • Table 20. Global Oligonucleotide Conjugates Sales Market Share in Value by Application (2020-2025)
  • Table 21. Global Oligonucleotide Conjugates Sales Market Share in Value by Application (2026-2031)
  • Table 22. Global Oligonucleotide Conjugates Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 23. Global Oligonucleotide Conjugates Sales Value by Region (2020-2025) & (US$ Million)
  • Table 24. Global Oligonucleotide Conjugates Sales Value by Region (2026-2031) & (US$ Million)
  • Table 25. Global Oligonucleotide Conjugates Sales Value by Region (2020-2025) & (%)
  • Table 26. Global Oligonucleotide Conjugates Sales Value by Region (2026-2031) & (%)
  • Table 27. Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 28. Key Countries/Regions Oligonucleotide Conjugates Sales Value, (2020-2025) & (US$ Million)
  • Table 29. Key Countries/Regions Oligonucleotide Conjugates Sales Value, (2026-2031) & (US$ Million)
  • Table 30. WuXi TIDES Basic Information List
  • Table 31. WuXi TIDES Description and Business Overview
  • Table 32. WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions
  • Table 33. Revenue (US$ Million) in Oligonucleotide Conjugates Business of WuXi TIDES (2020-2025)
  • Table 34. WuXi TIDES Recent Developments
  • Table 35. Bachem Basic Information List
  • Table 36. Bachem Description and Business Overview
  • Table 37. Bachem Oligonucleotide Conjugates Products, Services and Solutions
  • Table 38. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Bachem (2020-2025)
  • Table 39. Bachem Recent Developments
  • Table 40. Lonza Basic Information List
  • Table 41. Lonza Description and Business Overview
  • Table 42. Lonza Oligonucleotide Conjugates Products, Services and Solutions
  • Table 43. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Lonza (2020-2025)
  • Table 44. Lonza Recent Developments
  • Table 45. BioSpring Basic Information List
  • Table 46. BioSpring Description and Business Overview
  • Table 47. BioSpring Oligonucleotide Conjugates Products, Services and Solutions
  • Table 48. Revenue (US$ Million) in Oligonucleotide Conjugates Business of BioSpring (2020-2025)
  • Table 49. BioSpring Recent Developments
  • Table 50. GenScript Basic Information List
  • Table 51. GenScript Description and Business Overview
  • Table 52. GenScript Oligonucleotide Conjugates Products, Services and Solutions
  • Table 53. Revenue (US$ Million) in Oligonucleotide Conjugates Business of GenScript (2020-2025)
  • Table 54. Medtide (CPC Scientific) Basic Information List
  • Table 55. Medtide (CPC Scientific) Description and Business Overview
  • Table 56. Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions
  • Table 57. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Medtide (CPC Scientific) (2022-2025)
  • Table 58. Medtide (CPC Scientific) Recent Developments
  • Table 59. Kaneka Corporation (Eurogentec) Basic Information List
  • Table 60. Kaneka Corporation (Eurogentec) Description and Business Overview
  • Table 61. Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions
  • Table 62. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Kaneka Corporation (Eurogentec) (2020-2025)
  • Table 63. Olon (GTP Bioways) Basic Information List
  • Table 64. Olon (GTP Bioways) Description and Business Overview
  • Table 65. Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions
  • Table 66. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Olon (GTP Bioways) (2023-2025)
  • Table 67. Olon (GTP Bioways) Recent Developments
  • Table 68. Abzena Basic Information List
  • Table 69. Abzena Description and Business Overview
  • Table 70. Abzena Oligonucleotide Conjugates Products, Services and Solutions
  • Table 71. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Abzena (2020-2025)
  • Table 72. 3PBIOVIAN Basic Information List
  • Table 73. 3PBIOVIAN Description and Business Overview
  • Table 74. 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions
  • Table 75. Revenue (US$ Million) in Oligonucleotide Conjugates Business of 3PBIOVIAN (2022-2025)
  • Table 76. Bio-Synthesis Inc Basic Information List
  • Table 77. Bio-Synthesis Inc Description and Business Overview
  • Table 78. Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Bio-Synthesis Inc (2020-2025)
  • Table 80. ChemExpress Basic Information List
  • Table 81. ChemExpress Description and Business Overview
  • Table 82. ChemExpress Oligonucleotide Conjugates Products, Services and Solutions
  • Table 83. Revenue (US$ Million) in Oligonucleotide Conjugates Business of ChemExpress (2023-2025)
  • Table 84. Creative Biolabs Basic Information List
  • Table 85. Creative Biolabs Description and Business Overview
  • Table 86. Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions
  • Table 87. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Creative Biolabs (2020-2025)
  • Table 88. HitGen Basic Information List
  • Table 89. HitGen Description and Business Overview
  • Table 90. HitGen Oligonucleotide Conjugates Products, Services and Solutions
  • Table 91. Revenue (US$ Million) in Oligonucleotide Conjugates Business of HitGen (2023-2025)
  • Table 92. Pharmaron Basic Information List
  • Table 93. Pharmaron Description and Business Overview
  • Table 94. Pharmaron Oligonucleotide Conjugates Products, Services and Solutions
  • Table 95. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Pharmaron (2024-2025)
  • Table 96. Suzhou Biosyntech Basic Information List
  • Table 97. Suzhou Biosyntech Description and Business Overview
  • Table 98. Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Suzhou Biosyntech (2024-2025)
  • Table 100. Creative Biogene (IntegrateRNA) Basic Information List
  • Table 101. Creative Biogene (IntegrateRNA) Description and Business Overview
  • Table 102. Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions
  • Table 103. Revenue (US$ Million) in Oligonucleotide Conjugates Business of Creative Biogene (IntegrateRNA) (2020-2025)
  • Table 104. Key Raw Materials Lists
  • Table 105. Raw Materials Key Suppliers Lists
  • Table 106. Oligonucleotide Conjugates Downstream Customers
  • Table 107. Research Programs/Design for This Report
  • Table 108. Key Data Information from Secondary Sources
  • Table 109. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Oligonucleotide Conjugates Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 2. Global Oligonucleotide Conjugates Sales Value (2020-2031) & (US$ Million)
  • Figure 3. Oligonucleotide Conjugates Report Years Considered
  • Figure 4. Global Oligonucleotide Conjugates Players Revenue Ranking (2024) & (US$ Million)
  • Figure 5. The 5 Largest Companies in the World: Market Share by Oligonucleotide Conjugates Revenue in 2024
  • Figure 6. The 10 Largest Companies in the World: Market Share by Oligonucleotide Conjugates Revenue in 2024
  • Figure 7. Oligonucleotide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Oligonucleotide-Peptide Picture
  • Figure 9. Oligonucleotide-Antibody Picture
  • Figure 10. Oligonucleotide-GalNAc Picture
  • Figure 11. Oligonucleotide-Lipid Picture
  • Figure 12. Oligonucleotide-Aptamer Picture
  • Figure 13. Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Oligonucleotide Conjugates Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Oligonucleotide Conjugates Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Oligonucleotide Conjugates Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Key Countries/Regions Oligonucleotide Conjugates Sales Value (%), (2020-2031)
  • Figure 26. United States Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 28. United States Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 29. Europe Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 31. Europe Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 32. China Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 34. China Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 35. Japan Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 37. Japan Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 38. South Korea Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 40. South Korea Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Australia Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Australia Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 44. India Oligonucleotide Conjugates Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031
  • Figure 46. India Oligonucleotide Conjugates Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Oligonucleotide Conjugates Industrial Chain
  • Figure 48. Bottom-up and Top-down Approaches for This Report
  • Figure 49. Data Triangulation
  • Figure 50. Key Executives Interviewed